{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 7,
  "pageCount": 24,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/7",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.17,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "image",
      "text": "Emerging Product Profile",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca125bb9-93f8-4aa2-9841-f9e8a7597404",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.23,
        "y": 0.23
      },
      "kind": "list",
      "text": "Potent KIT inhibitor; High kinome selectivity; Depleted mast cells in relevant GI, skin and lung tissues of rats and dogs; Demonstrated efficacy in rat models of dermal anaphylaxis and asthma; Favorable pharmacokinetic profile including high oral bioavailability and metabolic stability; No evidence of structural or off-target liabilities; all tox findings on-target and believed to be reversible; Avoids mAb-related risks of infusion events and anaphylaxis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2af16f7-5475-40da-8155-f1dbcf8b7681",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.76,
        "x": 0.12,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "KIT, CSF1R, PDGFR-beta and PDGFR-alpha most potently inhibited in 231 and 40 kinase panels in biochemical assays and cell based assays, respectively. GI=gastrointestinal; CSF1R=colony stimulating factor 1 receptor; FMS=Feline McDonough sarcoma tyrosine kinase receptor; PDGFR=platelet derived growth factor; FLT3=FMS-related receptor tyrosine kinase 3; mAb=monoclonal antibody",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17d6582a-cdfe-40be-94c7-b1ee41a4049b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.32,
        "x": 0.64,
        "y": 0.28
      },
      "kind": "table",
      "text": "Inhibition of Kinases by THB001 in Ba/F3 Assays: KIT (0.02, -), CSF1R (0.95, 48), PDGFR-beta (2.11, 106), PDGFR-alpha (3.95, 198), FLT3 (>10.7, >535)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37fc6251-a144-45cc-96a3-b1edd970cb94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.635,
        "x": 0.036,
        "y": 0.065
      },
      "kind": "title",
      "text": "THB001: Highly Selective Oral Wild-Type KIT Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b40bc63e-48b4-4dbb-8c04-6aa56fe7cfa9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "353ff090-edc8-4601-a91c-640a0f6f4d83",
      "evidence": "table/data: Inhibition of Kinases by THB001 in Ba/F3 Assays: KIT (0.02, -), CSF1R (0.95, 48), PDGFR-beta (2.11, 106), PDGFR-alpha (3.95, 198), FLT3 (>10.7, >535)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "56e9f7b6-e6ea-4b9d-b393-88a0ff25d5c3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents the solution on pages 7 and 8, introducing THB001 as a highly selective oral wild-type KIT inhibitor.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}